EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co’s (NYSE:LLY) rheumatoid arthritis drug for an initial…
FDA AdCom In Favor Of Delaying Incyte’s Retifanlimab Approval In Anal Cancer
Members of the Oncologic Drugs Advisory Committee recommended with a 13-4 vote to defer a regulatory decision on Incyte Corporation’s (NASDAQ:INCY) retifanlimab…
RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $88
RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and lowers the price target from $92 to $88.
Incyte Highlights Outcome Of FDA Oncologic Drugs Advisory Committee Meeting Reviewing Retifanlimab As Treatment For Patients With Squamous Cell Carcinoma Of The Anal Canal
Incyte (NASDAQ:INCY) today announced the outcome of a meeting of the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA), which reviewed the Biologics License Application (BLA) for
The Daily Biotech Pulse: Lilly Spikes On Alzheimer’s Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
Incyte Shares See Volume; Traders Circulate FDA Release Considering Delaying Decision On Co’s Retifanlumab For Treatment Of Advanced Or Metastatic SCAC
https://www.fda.gov/media/150247/download
Benzinga Pro’s Top 5 Stocks To Watch For Monday, Jun. 21, 2021: WISH, INCY, CFLT, BBBY, PLUG
Today's 5 Stock Ideas
ContextLogic (WISH) - One of the most-searched tickers in Benzinga Pro over the last 24 hours and also one of the most discussed stocks in the Benzinga Pro chat Monday morning.
Incyte
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.
Incyte Announces FDA Has Extended New Drug Application Review Period For Ruxolitinib Cream For Treatment Of Atopic Dermatitis To Sept. 21 To Allow Time To Review Additional Analyses Submitted In Response To FDA’s Information Request
Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ruxolitinib cream for the treatment of atopic
Incyte, MorphoSys Announce 3-Year Results From Phase 2 L-MIND Study Of Tafasitamab In Combination With Lenalidomide For Treatment Of Relapsed Or Refractory DLBCL
-- Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Incyte (NASDAQ:INCY) and MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG ((FSE: